A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.
Checked against the public recordLast updated Feb 19, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Eli Lilly and Company
- Interventions being studied
- Drug: LY3200882; Drug: Pembrolizumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing on this study \[for example, nivolumab, pembrolizumab, atezolizumab\] * Participants must be willing to have tumor biopsies * Participants must have adequate organ function * Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 * Participants must be able to swallow tablets * Participants with stable, previously treated brain metastases may participate if neurologic symptoms have resolved and participants have been off steroids for at least 14 days Exclusion Criteria: * Participants must not have moderate or severe cardiovascular disease * Participants must not have active autoimmune disease (for example Crohn's disease, Hashimotos disease, etc) * Participants must not have an active infection requiring treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Dana Farber Cancer InstituteBoston, Massachusetts
- CHU de Besancon Hopital Jean MinjozBesançon
- Gustave RoussyVillejuif
- Institut Catala d'OncologiaL'Hospitalet de Llobregat, Barcelona
- Hospital Clinic I ProvincialBarcelona
- Hospital Madrid Norte SanchinarroMadrid
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 19, 2020. Always confirm current availability with the study team.